285 related articles for article (PubMed ID: 21114387)
1. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.
Kale-Pradhan PB; Morgan G; Wilhelm SM; Johnson LB
Pharmacotherapy; 2010 Dec; 30(12):1207-13. PubMed ID: 21114387
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
3. Candidemia and invasive candidiasis in adults: A narrative review.
Antinori S; Milazzo L; Sollima S; Galli M; Corbellino M
Eur J Intern Med; 2016 Oct; 34():21-28. PubMed ID: 27394927
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
5. Development of New Strategies for Echinocandins: Progress in Translational Research.
Walsh TJ; Azie N; Andes DR
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
[TBL] [Abstract][Full Text] [Related]
6. Treatment of invasive candidiasis: between guidelines and daily clinical practice.
Tagliaferri E; Menichetti F
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):685-9. PubMed ID: 25818660
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of candidemia and invasive candidiasis according to guidelines].
Glöckner A
Mycoses; 2010 May; 53 Suppl 1():30-5. PubMed ID: 20433654
[TBL] [Abstract][Full Text] [Related]
9. Treatment of invasive candidiasis with echinocandins.
Glöckner A; Steinbach A; Vehreschild JJ; Cornely OA
Mycoses; 2009 Nov; 52(6):476-86. PubMed ID: 19076282
[TBL] [Abstract][Full Text] [Related]
10. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.
Kontoyiannis DP; Bassetti M; Nucci M; Capparella MR; Yan JL; Aram J; Hogan PA
Mycoses; 2017 Oct; 60(10):663-667. PubMed ID: 28597967
[TBL] [Abstract][Full Text] [Related]
11. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
Tapısız A
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):339-46. PubMed ID: 21417873
[TBL] [Abstract][Full Text] [Related]
12. [Echinocandins in invasive candidiasis].
Glöckner A; Cornely OA
Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
[TBL] [Abstract][Full Text] [Related]
13. Echinocandins: The Expanding Antifungal Armamentarium.
Aguilar-Zapata D; Petraitiene R; Petraitis V
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
15. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
[TBL] [Abstract][Full Text] [Related]
17. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis.
Fernández-Ruiz M; Aguado JM; Almirante B; Lora-Pablos D; Padilla B; Puig-Asensio M; Montejo M; García-Rodríguez J; Pemán J; Ruiz Pérez de Pipaón M; Cuenca-Estrella M; ; ;
Clin Infect Dis; 2014 May; 58(10):1413-21. PubMed ID: 24642553
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis.
Demir KK; Butler-Laporte G; Del Corpo O; Ekmekjian T; Sheppard DC; Lee TC; Cheng MP
Mycoses; 2021 Sep; 64(9):1098-1110. PubMed ID: 33894072
[TBL] [Abstract][Full Text] [Related]
19. Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
Perkhofer S; Hell M; Gustorff B; Von Goedecke A; Illievich U; Kratzer C; Moosbauer W; Wimmer P; Zerlauth U; Nachbaur K; Vogel W; Bellmann R; Schwameis F; Lass-Flörl C
J Chemother; 2011 Oct; 23(5):285-9. PubMed ID: 22005061
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
